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γ-aminobutyric acid type A receptors (GABAARs), the major inhibitory neurotransmitter receptors in the mammalian central
nervous system, are arguably the most challenging member of the pentameric Cys-loop receptors to study due to their
heteromeric structure. When two or more subunits are expressed together in heterologous systems, receptors of variable
subunit type, ratio, and orientation can form, precluding accurate interpretation of data from functional studies. Subunit
concatenation is a technique that involves the linking of individual subunits and in theory allows the precise control of the
uniformity of expressed receptors. In reality, the resulting concatemers from widely used constructs are flexible in their
orientation and may therefore assemble with themselves or free GABAAR subunits in unexpected ways. In this study, we
examine functional responses of receptors from existing concatenated constructs and describe refinements necessary to allow
expression of uniform receptor populations. We find that dimers from two commonly used concatenated constructs, β-23-α
and α-10-β, assemble readily in both the clockwise and the counterclockwise orientations when coexpressed with free
subunits. Furthermore, we show that concatemers formed from new tetrameric α-10-β-α-β and α-10-β-α-γ constructs also
assemble in both orientations with free subunits to give canonical αβγ receptors. To restrict linker flexibility, we
systematically shorten linker lengths of dimeric and pentameric constructs and find optimized constructs that direct the
assembly of GABAARs only in one orientation, thus eliminating the ambiguity associated with previously described concatemers.
Based on our data, we revisit some noncanonical GABAAR configurations proposed in recent years and explain how the use of
some concatenated constructs may have led to wrong conclusions. Our results help clarify current contradictions in the
literature regarding GABAAR subunit stoichiometry and arrangement. The lessons learned from this study may guide future
efforts in understanding other related heteromeric receptors.
Introduction
γ-aminobutyric acid type A receptors (GABAARs) belong to the
Cys-loop superfamily of ligand-gated ion channels and are, as
the name implies, gated by γ-aminobutyric acid (GABA; for a
recent review, see Chua and Chebib [2017]). These receptors
play significant physiological roles in the mammalian brain and
are targets of a wide range of therapeutic drugs such as benzo-
diazepines and general anesthetics. Like other Cys-loop re-
ceptors, GABAARs are made up of five subunits encircling a
central ion pore. While identical subunits can assemble to form
homomeric receptors, it is more common for different subunits
to form heteromeric receptor combinations (or subtypes). Evi-
dence thus far suggests that binary, ternary, and quaternary
receptors (i.e., receptors made up of two, three, or four different
types of subunits, respectively) exist physiologically. Given the
19 mammalian GABAAR subunits (α1–6, β1–3, γ1–3, δ, π, ε, q, and
ρ1–3) cloned to date, this gives rise to a multitude of possible
receptor subtypes. While the actual number of receptor sub-
types expressed in vivo is less daunting than the theoretical
maximum (Olsen and Sieghart, 2008), there is still a striking
level of structural complexity that renders GABAARs one of the
most challenging members of Cys-loop receptors to study.
As most ligand binding sites are found in interfaces between
two subunits, pinning down the precise ratios of subunits and
how they orient themselves spatially in each receptor subtype is
a prerequisite for the accurate delineation of GABAAR function
and pharmacology. Therefore, researchers have resorted to
subunit concatenation to define subunit stoichiometry and ar-
rangement of heterologously expressed GABAARs. This tech-
nique fuses subunit complementary DNAs (cDNAs) with a linker
bridging the C terminus of the first subunit to the N terminus of
the second subunit, thus allowing multiple subunits to be ex-
pressed together as one entity. Following the creation of the first
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concatenated α6-β2 construct by Im et al. (1995), systematic
refinements performed by the Sigel group in the early 2000s
(Baumann et al., 2001, 2002; Minier and Sigel, 2004) have since
popularized the use of concatenated constructs in the GABAAR
field. Furthermore, the specific strategies devised by the Sigel
group have strongly influenced how subunits are concatenated
for nearly two decades (Baumann et al., 2003; Bracamontes and
Steinbach, 2009; Kaur et al., 2009; Shu et al., 2012; Botzolakis
et al., 2016).
Concatemers have contributed immensely to the under-
standing of assembly, function, and pharmacology of specific
GABAAR subtypes. In the case of the α1β2γ2 receptor, the most
ubiquitous GABAAR in the human brain, data collected with
the use of various dimeric, trimeric, tetrameric, and pentameric
concatemers overwhelmingly support a (α1)2(β2)2(γ2) stoichi-
ometry, with a subunit order of βαβαγ in a counterclockwise
orientation when viewed extracellularly. Recent cryogenic
electron microscopy structures have confirmed this stoichiom-
etry (Zhu et al., 2018). The two β2-α1 interfaces harbor GABA
binding sites and the α1-γ2 interface binds benzodiazepines and
zolpidem. Hence, there appear to be rules governing the for-
mation of GABAARs where certain subunits have specific roles
and assembly preferences. However, conflicting results
suggesting alternative assembly options have been reported
recently. In a study conducted by Botzolakis et al. (2016),
α1 and γ2 subunits appeared to have the ability to substitute
for a β2 subunit to give (α1)3(β2)(γ2) (βαγαα) and (α1)2(β2)(γ2)2
(βαγαγ) receptors. Other studies have reported that γ and δ
subunits might substitute for an α subunit leading to functional
binary βγ and βδ receptors (Chua et al., 2015; Lee et al., 2016;
Wongsamitkul et al., 2017). Hence, these studies raise the
possibility of substantial heterogeneity in the formation of
GABAARs.
While the concatenation technique is powerful, there are also
caveats associated with its use. In a review by Ericksen and
Boileau (2007), a number of these caveats were discussed for
the Cys-loop receptor field including proteolysis, optimal linker
length, clockwise versus counterclockwise concatemer assembly
and loop-outs. Perplexingly, some of the key points of this re-
view appear to have been largely ignored in the field, perhaps
because they were only backed by in silico modeling. Sigel et al.
(2009) later discussed the potential pitfalls specifically relating
to the GABAAR constructs designed by his group. This included
nonoptimal linker design and whether signal-peptide sequences
in downstream linked subunits should be omitted; however, the
possibility for clockwise as well as counterclockwise concatemer
assembly was not mentioned. Recently, we discovered that ex-
pression of published concatenated nicotinic acetylcholine re-
ceptor (nAChR) constructs in Xenopus laevis oocytes led to far
more complex receptor pools than anticipated (Ahring et al.,
2018). This was due to an ability of the linked concatemers to
orient themselves in both the clockwise and the counterclock-
wise directions. Due to this flexibility, receptor pools contained
mixtures of receptors with different stoichiometries whenever
ternary scenarios were examined. Most importantly, we addi-
tionally determined that optimized linker lengths can lead to
uniform nAChR receptor pools where functional receptors
primarily originate from concatemers assembled in the coun-
terclockwise orientation.
In this present study, we shift the focus to concatenated
GABAARs to evaluate whether previously designed GABAAR
constructs give uniform resultant receptor pools. As expected,
based on our previous work on the nAChRs, this is not the case.
Dimeric constructs and tetrameric constructs thereof lead to
dimers and tetramers, which have the inherent ability to as-
semble in both the clockwise and the counterclockwise ori-
entations. In an attempt to constrain this flexibility, we design a
range of dimeric and pentameric constructs with systematically
shortened linker lengths. We show that it is possible to obtain a
uniform receptor pool of ternary GABAARs using new optimized
concatenated constructs. Our work implies that previous con-
clusions based on data from concatenated constructs may need
to be reexamined. Based on our findings, we conclude that
GABAAR assembly may be less chaotic than proposed in recent
studies.
Materials and methods
Zolpidem was purchased from Toronto Research Chemicals.
GABA, kanamycin, theophylline, collagenase, HEPES, and all
salts or other chemicals not specifically mentioned were pur-
chased from Sigma-Aldrich and were of analytical grade.
Oligonucleotides were purchased from Sigma-Aldrich, and se-
quencing services were from Australian Genome Research Fa-
cility. Restriction enzymes, Q5 polymerase, T4 DNA ligase, and
10-beta competent Escherichia coli were from New England Bi-
olabs. DNA purification kits were from Qiagen. The Quick-
Change II Site-Directed Mutagenesis kit was from Agilent
Technologies, and the mMessage mMachine T7 transcription kit
was from ThermoFisher Scientific.
Molecular biology
Human cDNA for wild-type monomeric α1, β2, and γ2s GABAAR
subunits and a concatenated construct thereof, β2-23-α1, were
kind gifts from Saniona A/S. Naturally occurring BamHI,
HindIII, and KpnI restriction sites in the α1 and β2 subunit se-
quences, which would interfere with the concatenation strategy,
were initially removed by silent mutations using site-directed
mutagenesis. In the following, amino acids are represented by
their single-letter code. Point mutated γ2A79R and α1R67A sub-
units were likewise prepared using site-directed mutagenesis.
The numbering convention used is based on the mature peptide
sequences (i.e., after signal peptide cleavage). A79 corresponds
to the A118 residue in the full-length γ2 cDNA sequence, and R67
corresponds to the R94 residue in the full-length α1 cDNA se-
quence based on sequence information from UniProt with ac-
cession nos. P18507 and P14867, respectively. Note that the two
γ2A79R and α1R67A mutants essentially swap the homologous loop
D residues between these two subunits.
To generate new concatenated α1-xa-β2 constructs, where x
represents the number of amino acids (a) added or deleted while
linking the subunits, specific linker sequences and cloning re-
striction sites were added to the α1 and β2 cDNAs before the
final assembly procedure. In brief, AGS linker sequences were
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designed to contain a unique BamHI restriction site (embedded
in codons for GS) and antisense α1 as well as sense β2 oligonu-
cleotide sequences were fabricated to traverse this site. The
antisense α1 oligonucleotides caused in-frame fusion of the last
amino acid in α1 (PTPHQ456) to the AGS linker sequence. The
sense β2 oligonucleotides caused in-frame fusion of the AGS
linker sequence to the first amino acid in the predicted mature
β2 (Q25SVND) peptide (omission of the β2 signal peptide). The
remaining oligonucleotides were designed to match the re-
spective wild-type sequences and include suitable restriction
sites for cloning purposes. Standard PCR reactions with α1 or
β2 as template were performed using Q5 polymerase, and PCR
products were cloned into in-house vectors using restriction
digestion and ligation. Correct introduction of linker sequences
and fidelity of all coding sequences were then verified by
double-stranded sequencing. Thereafter, concatenated con-
structs were created by restriction digestion and ligation using
the unique AGS linker BamHI site. The α1-10-β2 (α1-LQ9-β2)
construct was built in a similar manner with the linker sequence
containing a unique PstI restriction site (embedded in codons
for LQ). Likewise, tetrameric and pentameric constructs of α1,
β2, and γ2s subunits were built by using 3–4 different linker
sequences where each contained either a unique BamHI (em-
bedded in codons for GS), HindIII (embedded in codons for GSL),
KpnI (embedded in codons for GT), or AgeI (embedded in codons
for TG) restriction site (Table 3). E. coli 10-beta bacteria were
used as hosts for plasmid amplification, and plasmid purifica-
tions were performed with standard kits (Qiagen). Comple-
mentary RNA (cRNA) was produced from linearized cDNA using
the mMessage mMachine T7 Transcription kit according to the
manufacturer’s descriptions and stored at −80°C until use. For
tetrameric and pentameric constructs, which represent long
transcripts, the guanosine triphosphate concentration was in-
creased to give a final cap analog (m7G(59)ppp(59)G) to guano-
sine triphosphate ratio of 2:1.
Modeling
A homologymodel of an α1-β2-α1 trimerwas constructed using a
human GABAAR β3 homo-pentamer as template (Miller and
Aricescu, 2014). The template x-ray structure (PDB accession
no. 4COF) was downloaded from the RCSB Protein Data Bank
(www.rcsb.org) and prepared following the protocol for protein
preparation implemented in Maestro 11.2 (Schrödinger Release
2017–2: Maestro, Schrödinger). Query sequences for the human
α1 and β2 GABAARs were obtained from UniProt with accession
nos. P14867 and P47870, respectively. Signal peptides, the sec-
ond intracellular loop, and C-terminal tails, for which no tem-
plate exists in the 4COF structure, were deleted from the
sequences. Query sequences were then aligned to chains E, A,
and B of the template to give the α1-β2-α1 trimer. Twentymodels
were constructed using Prime, and the model with the best
Prime score was selected for further refinement involving loop
sampling of the β2 N terminus. To illustrate linker orientations,
the disordered N-terminal part of the β2 subunit was sculpted
toward the C terminus of the neighboring α1 subunits in the
clockwise and counterclockwise directions, respectively. The
gap between the last modeled residue in the α1 C terminus
(WATYL443) and the β2 N terminus was subsequently bridged
with AGS repeats in such a way that a subsequent geometry
optimization (Macromodel) did not lead to significant distortion
or displacement of helices at either end of the linker.
Expression of GABAARs in X. laevis oocytes
Oocytes were obtained and prepared as previously described
(Mirza et al., 2008). Briefly, to obtain isolated oocytes, lobes
from ovaries were removed from anesthetized adult female X.
laevis frogs following a protocol approved by the Animal Ethics
Committee of The University of Sydney (reference number:
2013/5915). To obtain isolated oocytes, ovary lobes were sliced
into small pieces using surgical knives and defolliculated by
collagenase treatment. Stage V and VI oocytes were injected
with ∼50 nl of a 0.5 ng/nl cRNA mixture encoding the desired
GABAAR subunits and incubated for 3–5 d at 18°C in modified
Barth’s solution (96 mMNaCl, 2.0 mMKCl, 1 mMMgCl2, 1.8 mM
CaCl2, 5 mM HEPES, 2.5 mM sodium pyruvate, 0.5 mM theo-
phylline, and 100 µg/ml gentamycin; pH 7.4).
Electrophysiology
Electrophysiological recordings using the two-electrode voltage-
clamp technique were performed as described previously (Mirza
et al., 2008; Ahring et al., 2016; Kowal et al., 2018). Briefly, oo-
cytes were placed in a custom-built recording chamber and
continuously perfused with a saline solution termed ND96
(96 mMNaCl, 2 mMKCl, 1 mMMgCl2, 1.8 mMCaCl2, and 10mM
HEPES; pH 7.4). Pipettes were backfilled with 3 M KCl, and open
pipette resistances ranged from 0.4 to 2 MΩwhen submerged in
ND96 solution. Cells were voltage clamped at a holding potential
of −60mV using an Axon GeneClamp 500B amplifier (Molecular
Devices). Oocytes with initial leak currents exceeding 300 nA
when clamped were discarded. Amplified currents were filtered
at 20 Hz by a four-pole low-pass Bessel filter (Axon GeneClamp
500B), digitized by a Digidata 1440A (Molecular Devices), and
sampled at 200 Hz as well as analyzed on a personal computer
using the pClamp 10.2 suite (Molecular Devices). Responses to
individual applications were collected as episodic traces fol-
lowing triggering events.
GABA was dissolved in ultrapure water at a concentration of
316 mM, while zolpidem was dissolved as a 100-mM stock so-
lution in DMSO. The maximal concentration of DMSO in per-
fusates was always <0.1% and this did not evoke any measurable
currents from wild-type α1β2γ2 receptors. Stock solutions were
stored at −20°C. Fresh GABA and zolpidem dilutions were pre-
pared in ND96 solution on the day of the experiment. To ensure
rapid solution exchange in the immediate oocyte vicinity, a 1.5-
mm diameter capillary tube was placed ∼2 mm from the oocyte.
By way of this capillary tube, oocytes were continuously per-
fused with saline ND96 solution or test application at a flow rate
of 2.0ml/min. Each application lasted∼30 s andwas followed by
a 2–5-min washout period depending on the ligand concentra-
tion of a given application.
Experimental protocols
To determine the concentration–response relationships (CRRs)
of different constructs, five to seven concentrations of GABA or
Liao et al. Journal of General Physiology 800
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zolpidem were applied to each oocyte. To ensure reproducibility
of evoked current amplitudes, a set of control applications was
performed before the CRR experiments. These were as follows:
three GABAcontrol (2–100 µM; approximately EC5-30 depending
on receptor type) applications, one GABAmax (316–10,000 µM;
approximately EC100) application, and another three GABAcontrol
applications. Increasing concentrations of GABA alone or zolpi-
dem coapplied with GABAcontrol were applied after the control
experiments. Final datasets for GABA and zolpidem were as-
sembled from a minimum of five experiments conducted on a
minimum of two batches of oocytes. Single data points were
generally not excluded from calculations; instead, all data from
oocytes with incomplete CRRs or erratic control GABA responses
were excluded.
Data analysis
Raw traces were analyzed using pClamp 10.2 (Molecular De-
vices). During analysis, episodic traces for each individual ap-
plication were overlaid and baseline subtracted. Peak current
amplitudes were quantified by measuring the maximum inward
current for each response. For GABA CRR experiments, peak
current amplitudes (I) of all responses were fitted to the Hill
equation and then normalized to the maximal fitted response
(Imax_fit_GABA) for each individual oocyte (I/Imax_fit_GABA). For
experiments with zolpidem, the compound was coapplied with
GABAcontrol (2–100 µM). Differences between GABAcontrol-
evoked current amplitudes in the absence or presence of zolpi-
dem (I) were calculated as the percentage change from the
GABAcontrol-evoked current: that is, ([I−IGABA_control] × 100)/
IGABA_control. The calculated zolpidem responses for each oocyte
were then fitted to the Hill equation and normalized to the
maximal fitted response (Imax_fit_zolpidem). All CRRs were fitted
by nonlinear regression to the Hill equation using GraphPad
Prism 7. Unless otherwise specified, a simple monophasic
model with three variables was used (i.e., fixed Hill slope of 1),
and efficacy at infinitely low compound concentrations was set
to 0. The model with fixed Hill slope was chosen universally
over a variable slope model for two main reasons: first, it
represented the statistically better choice for the majority of
the datasets according to the extra sum-of-squares F test; and
second, it limits overinterpretation of data in cases where Hill
slopes differ substantially from 1 due to mixed receptor pools.
Statistical analysis was performed using GraphPad Prism 7.
Results
In the present study, we performed analysis of receptors arising
from previously published as well as new concatenated GABAAR
constructs. X. laevis oocytes were injected with ∼25 ng of the
respective cRNA mixtures and incubated for 2–6 d before sub-
jection to two-electrode voltage-clamp electrophysiology. The
maximal GABA-evoked (GABAmax) peak-current amplitude and
a full GABA CRR were obtained at each individual oocyte. In
cases where the cRNA mixture contained a γ2 subunit, the da-
taset was complemented with full CRRs for zolpidem. The aim of
the zolpidem experiments is to assess for potential changes in
modulatory potency and most data are therefore normalized.
Note that SD error is used in the graphical representation of
CRRs, as the relatively minor variabilities often resulted in SEM
error bars being hidden by the data symbols.
GABA and zolpidem CRRs at wild-type α1β2 and
α1β2γ2 receptors
Like many other Cys-loop receptors, binary α1β2 GABAARs
can express in two stoichiometries, (α1)2(β2)3 or (α1)3(β2)2
(Baumann et al., 2001; Boileau et al., 2005; Che Has et al., 2016).
To obtain expression of receptor populations enriched in one
or the other of these stoichiometries, α1 and β2 cRNAs were
mixed in a biased 1:50 or 50:1 ratio. The α1β2γ2 receptor was
expressed using a biased cRNA ratio of 5:1:5 to ensure enrich-
ment of (α1)2(β2)2(γ2) receptors (Hartiadi et al., 2016).
The GABA CRRs at (α1)2(β2)3 and (α1)3(β2)2 receptors were
virtually identical with resulting fitted half maximal effective
concentration (EC50) values of 2.6 and 3.3 µM, respectively
(Fig. 1 A and Table 1). Incorporation of a γ2 subunit into the
receptor complex caused an ∼10-fold decrease in the GABA po-
tency resulting in a fitted EC50 value of 22 µM for (α1)2(β2)2(γ2)
receptors. Average GABAmax-evoked peak-current amplitudes
were in the range of 0.8–1.5 µA for the α1β2 receptor stoi-
chiometries, whereas larger currents of ∼3 µA were observed
once the γ2 subunit was integrated (Fig. 1 B and Table 1). No
effect of zolpidem was noted at either of the α1β2 receptor stoi-
chiometries, whereas the compound was a potent positive
modulator at the α1β2γ2 receptor with an EC50 value of 0.11 µM
(Fig. 1 C and Table 2). These data for GABA and zolpidem are
generally in good agreement with literature reports (Boileau
et al., 2005). In a recent report by Che Has et al. (2016), zol-
pidem modulation was observed at α1β3 receptors in the 3α:2β
stoichiometry; however, these findings could not be repro-
duced with the conditions used here.
Concatemers from the dimeric β-23-α and α-10-β constructs
can assemble in both the clockwise and the
counterclockwise orientations
To evaluate the expression and assembly pattern of concate-
nated GABAAR constructs, we initially tested two dimeric con-
structs termed β2-23-α1 and α1-10-β2 (β-23-α and α-10-β
hereafter). These were originally designed by the Sigel group
and have been widely used in the field (Baumann et al., 2001;
Bracamontes and Steinbach, 2009; Shu et al., 2012; Botzolakis
et al., 2016). The naming scheme indicates the number of amino
acids used to connect the C terminus of the first subunit to the
mature N terminus of the second subunit. The original linkers
contained primarily glutamine (Q) repeats, and in our replica
constructs either an identical [β-23-α, Q3(Q2A3PA)2AQ5] or vir-
tually identical (α-10-β, LQ9 instead of Q10) linker sequence was
used (Table 3). Oocytes were injected with cRNA for the dimer
constructs by themselves or in combinations with β2 or γ2 in a
1:1 ratio.
Dimeric constructs alone
Injection of cRNAs for β-23-α or α-10-β led to GABAmax-evoked
currents with average peak current amplitudes in the range of
0.5–0.8 µA (Fig. 2 A and Table 1). Hence, expressed dimers are
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clearly able to assemble into functional pentameric receptors.
GABA CRRs revealed fitted EC50 values of 3.0 and 2.8 µM for
β-23-α and α-10-β, respectively (Fig. 2, B and C; and Table 1).
This is in good agreement with the 2.6–3.3-µM range observed
for (α1)2(β2)3 and (α1)3(β2)2 receptors obtained with biased
cRNA ratios (Fig. 1 A) and suggests that these dimers form re-
ceptors that behave like regular α1β2 receptors formed from free
subunits. Disregarding the possibility of linker proteolysis, the
simplest explanation for these observations is that three dimers
come together to form a pentameric receptor with one dangling
subunit. As it is unknown whether the linkers direct the as-
sembly orientation, there are six possible assemblies leading to
receptors with two GABA-binding β2-α1 interfaces for each
construct (Fig. 3 A; note only β-23-α is depicted, but a similar
scenario exists for α-10-β). These have the linked subunits ori-
ented in either the clockwise, the counterclockwise, or both
orientations.
Dimeric constructs + b2
Coinjection of β-23-α or α-10-β with free β2 subunits led to
larger average GABAmax-evoked peak current amplitudes in the
2-µA range (Fig. 2 A and Table 1). This indicates that pentameric
receptor assembly is more efficient when dimers are mixed with
a free subunit, although the two- to fourfold difference appears
relatively modest. The GABA CRRs are virtually identical for the
two combinations, and the fitted EC50 values of 1.8–2.6 µM are in
good agreement with the value obtained for (α1)2(β2)3 using a
biased cRNA ratio (Fig. 2, B and C; and Table 1). The simplest
explanation for these observations is that two dimers form re-
ceptors with one β2 subunit. Given that the linkers may adopt
the clockwise and/or counterclockwise orientations, there are
three assembly possibilities for each construct that all yield
uniform 2α:3β stoichiometry receptors.
Dimeric constructs + γ2
Coinjection of β-23-α or α-10-β with γ2 led to substantially
larger GABAmax-evoked peak-current amplitudes in the ∼8-µA
range (Fig. 2 D and Table 1). The fourfold amplitude increase
compared with β2 coinjections could be due to a larger single-
channel conductance observed for γ2-containing receptors and/
or increased translocation of receptors to the oocyte cell surface
when a γ2 subunit is included (Angelotti and Macdonald, 1993;
Mortensen and Smart, 2006). The GABA CRRs are similar for the
two construct combinations with fitted EC50 values in the
9.2–14-µM range (Fig. 2, E and F; and Table 1). These values are
approximately twofold more potent than the 22 µM obtained for
(α1)2(β2)2(γ2) using a biased cRNA ratio, which might suggest
that receptor pools contain a small percentage of pollutant bi-
nary α1β2 receptors. The modulatory potency of zolpidem is in
the 0.1–0.18-µM range, irrespective of whether receptors orig-
inate from free subunits or cRNA combinations with the con-
catenated constructs (Fig. 1 C; Fig. 2, G and H; and Table 2).
While there are potentially three simple explanations for how
each dimer could assemble with a γ2 subunit, only one led to
canonical receptors that contain two GABA-binding β2-α1 in-
terfaces and one zolpidem-binding α1-γ2 interface (Fig. 3 B,
receptor 1 and 4). The other two assembly possibilities result in
receptors with only one GABA-binding interface and it is
questionable whether these are functional (addressed further
below). Interestingly, to yield canonical receptors, the dimer
linkers have to be orientated in a counterclockwise orientation
for β-23-α + γ2 but a clockwise orientation for α-10-β + γ2.
Figure 1. Potency of GABA and zolpidem at α1β2 and α1β2γ2 GABAARs. X. laevis oocytes were injected with cRNAmixtures of α1, β2, and γ2 subunits in the
indicated ratios and subjected to two-electrode voltage-clamp electrophysiology as described in the Materials and methods. Biased cRNA ratios were used to
ensure enriched populations of (α1)3(β2)2, (α1)2(β2)3, and (α1)2(β2)2(γ2) receptors. An approximate total of 25 ng cRNA was injected in a volume of 50 nl.
(A) Baseline subtracted GABA-evoked peak-current amplitudes (I) for receptors from the indicated cRNA mixtures were fitted to the Hill equation by nonlinear
regression and normalized to themaximal fitted values (Imax_fit_GABA). Normalized responses are depicted as mean ± SD as a function of the GABA concentration
(in M), and they are fitted to the Hill equation with a fixed bottom of 0 and a Hill slope of 1. Data were obtained from n = 10–17 experiments, and regression
results are presented in Table 1. (B) GABAmax-evoked peak-current amplitudes from the experiments in A are depicted as means ± SEM and calculated averages
are presented in Table 1. A GABA concentration of 316 µM was used as GABAmax. (C) Zolpidem enhancement of GABA-evoked currents was evaluated for (α1)
3(β2)2, (α1)2(β2)3, and (α1)2(β2)2(γ2) receptors by co-application with a submaximal control concentration of GABA (2–5 µM). Baseline subtracted peak-current
amplitudes (I) were expressed as percent change from IGABA_control (% modulation) and are depicted as means ± SD as a function of the zolpidem concentration
(in M). Data points were fitted by nonlinear regression to the Hill equation with a fixed bottom of 0 and Hill slope of 1. The maximal fitted response for the
α1β2γ2 receptor was 270% ± 10%, whereas no positive modulation was observed at the two α1β2 receptors. Data were obtained from n = 6–11 experiments
and regression results are presented in Table 2.
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Table 1. Regression results from fitted GABA-evoked responses at wild-type and concatenated GABAARs
GABA
Construct Subunit Emax EC50 (µM) pEC50 n GABAmax (nA)
α1 + β2 1:50 0.99 ± 0.01 2.6 5.58 ± 0.03 12 1,500 ± 200
α1 + β2 50:1 0.99 ± 0.02 3.2 5.49 ± 0.03 17 750 ± 120
α1 + β2 + γ2 5:1:5 1.00 ± 0.01 22 4.66 ± 0.03 10 3,200 ± 400
Dimeric constructs
β2-23-α1 1.00 ± 0.02 3.0 5.53 ± 0.04 12 480 ± 100
β2-23-α1 β2 1.00 ± 0.02 2.6 5.58 ± 0.03 10 1,900 ± 200
β2-23-α1 γ2 1.00 ± 0.02 9.2 5.04 ± 0.04 8 8,400 ± 600
α1-10-β2 1.00 ± 0.01 2.8 5.55 ± 0.03 11 820 ± 190
α1-10-β2 β2 1.00 ± 0.01 1.8 5.75 ± 0.02 13 1,800 ± 200
α1-10-β2 γ2 1.00 ± 0.02 14 4.84 ± 0.04 10 8,100 ± 600
α1-9a-β2 1.00 ± 0.01 3.2 5.49 ± 0.03 10 190 ± 60
α1-9a-β2 β2 1.00 ± 0.02 1.7 5.77 ± 0.04 11 1,200 ± 300
α1-9a-β2 γ2 0.99 ± 0.01 17 4.77 ± 0.03 20 11,000 ± 1,000
α1-6a-β2 0.99 ± 0.01 5.7 5.24 ± 0.03 11 140 ± 30
α1-6a-β2 β2 1.00 ± 0.01 2.3 5.65 ± 0.02 11 1,300 ± 300
α1-6a-β2 γ2 1.00 ± 0.02 41 4.38 ± 0.04 10 3,100 ± 300
α1-3a-β2 1.00 ± 0.02 10 4.99 ± 0.04 10 89 ± 28
α1-3a-β2 β2 1.00 ± 0.02 3.2 5.49 ± 0.03 9 630 ± 110
α1-3a-β2 γ2 0.99 ± 0.02 34 4.46 ± 0.04 12 4,300 ± 500
α1-0a-β2 N/A 19 34 ± 10
α1-0a-β2 β2 1.00 ± 0.01 3.5 5.45 ± 0.02 14 630 ± 100
α1-0a-β2 γ2 0.99 ± 0.03 130 3.88 ± 0.05 11 500 ± 140
α1-(-1a)-β2 N/A 21 No current
α1-(-1a)-β2 β2 0.99 ± 0.01 2.6 5.58 ± 0.03 7 400 ± 140
α1-(-1a)-β2 γ2 0.99 ± 0.02a 140a 3.84 ± 0.04a 18 7.8 ± 1.9b
α1-(-2a)-β2 N/A 15 No current
α1-(-2a)-β2 β2 1.00 ± 0.01 2.6 5.59 ± 0.03 11 470 ± 90
α1-(-2a)-β2 γ2 1.00 ± 0.01a 130a 3.90 ± 0.03a 17 8.0 ± 3.6b
α1-(-3a)-β2 N/A 21 No current
α1-(-3a)-β2 β2 0.96 ± 0.04 4.0 5.40 ± 0.08 8 40 ± 9
α1-(-3a)-β2 γ2 1.00 ± 0.01a 64a 4.20 ± 0.02a 24 2.3 ± 0.9b
Tetrameric constructs
α1-10-β2-α1-β2 N/A 13 60 ± 13
α1-10-β2-α1-β2 γ2 0.99 ± 0.02 32 4.50 ± 0.03 17 6,500 ± 1,000
α1-10-β2-α1-γ2 N/A 15 150 ± 25
α1-10-β2-α1-γ2 β2 0.96 ± 0.03 34 4.47 ± 0.05 19 4,700 ± 400
Pentameric constructs
α1-(-1a)-β2-α1-β2-γ2 0.99 ± 0.01 390 3.41 ± 0.02 19 320 ± 40
α1-(-1a)-β2-α1-γ2-β2 1.00 ± 0.01 330 3.49 ± 0.02 16 3,500 ± 400
γ2-15a-β2-α1-β2-α1 0.99 ± 0.03 51 4.30 ± 0.04 11 4,900 ± 600
γ2-13a-β2-α1-β2-α1 0.99 ± 0.02 70 4.16 ± 0.03 12 5,300 ± 500
γ2-11a-β2-α1-β2-α1 0.99 ± 0.01 110 3.96 ± 0.02 17 3,300 ± 500
γ2-10a-β2-α1-β2-α1 0.99 ± 0.02 120 3.92 ± 0.04 10 3,100 ± 700
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In summary, injection of cRNA for dimeric β-23-α or α-10-β
constructs into oocytes either alone or in combination with free
β2 or γ2 subunits led to expression of functional receptors in all
cases. Based on the average current levels, there was no differ-
ence in how well the two constructs express. While data for the
binary scenarios did not reveal specific information regarding
assembly orientation, the ternary scenarios with free γ2 sub-
units showed that the dimers oriented themselves in opposite
orientations. Finally, it is important to note that we only dis-
cussed and illustrated the simplest assembly scenarios and more
complex scenarios cannot be excluded. These could include di-
pentamers or receptors with numerous dangling subunits, as
suggested by Groot-Kormelink et al. (2004) for nAChRs.
Concatemers from tetrameric constructs based on α-10-β can
assemble in both orientations
To further substantiate that concatemers with nonoptimal
linker lengths can assemble in both orientations, we designed
new tetrameric constructs. For reasons that will be explained
below (“Design of new dimeric constructs” section), we were
particularly interested in generating constructs with α1 as the
first subunit. Two new constructs, α-10-β-α-β and α-10-β-α-γ,
were made by extending the α-10-β construct using primarily
AGS repeats for the new linkers. Note that these constructs
differ by having a β2 or a γ2 subunit in the fourth construct
position. To prevent new linkers in the constructs from nega-
tively affecting assembly and/or function of the receptors
formed, linkers longer than those in β-23-α and α-10-β dimers
were used. Using our total-linker-length calculation
methodology, which is explained in the next section, the β-23-α
and α-10-β constructs have “total linker lengths” ranging from
37 to 41 amino acids, and we chose to standardize on 45 amino
acids for the new linkers (Table 3). An (AGS)5LGS(AGS)3 linker
was used to fuse the β2second-α1third subunit and consists of nine
AGS repeats, where one repeat was altered from AGS to LGS to
allow introduction of a unique restriction (HindIII) site. An
AGT(AGS)5 linker was used to fuse the α1third-β2fourth pair and
consists of six AGS repeats with one repeat altered to AGT to
allow a unique restriction (KpnI) site. An AGT linker consisting
of one repeat was used to fuse the α1third-γ2fourth pair. Note that,
although the specific linker sequences added to fuse these
subunit pairs contained a different number of AGS repeats, the
total linker length remains the same at 45 amino acids in all
cases due to naturally occurring N- and C-terminal sequences
(further explained in the next section).
Injection of cRNA for the tetrameric constructs alone resulted
in GABAmax-evoked peak-current amplitudes in the 60–150-nA
range (Table 1). Hence, in agreement with observations for
dimers, tetramers are also able to assemble into functional re-
ceptors by themselves, likely with three dangling subunits. To
accomplish normal pentameric assembly, the tetrameric con-
structs were next coexpressed with a free γ2 or β2 subunit. As
expected, α-10-β-α-β + γ2 and α-10-β-α-γ + β2 coinjections led to
substantially larger and similar GABAmax-evoked peak-current
amplitudes in the ∼5–7-µA range (Fig. 4 A). Full CRRs revealed
fitted EC50 values in the 32–34-µM range for GABA (Fig. 4, B and
C) and in the 0.092–0.10-µM range for zolpidem (Fig. 4 D).
These values are essentially identical to the values observedwith
Table 1. Regression results from fitted GABA-evoked responses at wild-type and concatenated GABAARs (Continued)
GABA
Construct Subunit Emax EC50 (µM) pEC50 n GABAmax (nA)
γ2-9a-β2-α1-β2-α1 1.00 ± 0.01 120 3.92 ± 0.02 15 890 ± 160
Mutant constructs
α1-9a-β2 γ2(A118R) 0.99 ± 0.02 30 4.52 ± 0.04 13 8,700 ± 1,500
α1-0a-β2 γ2(A118R) 1.00 ± 0.01 110 3.98 ± 0.02 9 600 ± 90
α1R94A + β2 + γ2 5:1:5 0.99 ± 0.02 1,100c 2.97 ± 0.03c 10 7,100 ± 400
γ2-11a-β2-α1-β2-α1R94A 1.01 ± 0.01 2,600c 2.58 ± 0.02c 14 3,600 ± 300
γ2-11a-β2-α1-β2-α1R94A α1 0.97 ± 0.02c,d 2,000c,d 2.70 ± 0.03c,d 12 1,700 ± 200
Data points were fitted to the Hill equation with the bottom set to 0 and Hill slope set to 1 by nonlinear regression. Normalized fitted maximal responses of
GABA are presented as Emax ± SEM. Fitted potencies of GABA are presented as EC50 in µM and pEC50 ± SEM where p = −Log for the indicated number (n) of
individual oocytes. The average maximal current obtained with GABAmax applications is presented as GABAmax ± SEM in nA for the tested oocytes. For α-10-
β+γ2, a GABA concentration of 3,160 µM was used to establish GABAmax-evoked peak currents amplitudes, whereas a concentration of 316 µM was used for
all remaining cRNA combinations of wild-type free subunits, binary constructs, and tetrameric constructs. For pentameric constructs and cRNA combinations
with mutant subunits, the GABAmax concentration was adjusted according to the EC50 value of GABA CRRs: for CRRs with EC50 values <70 µM, a
concentration of 316 µM was used; for CRRs with EC50 values between 70 and 500 µM, a concentration of 3,160 or 10,000 µM was used; and for CRRs with
EC50 values >500 µM, a concentration of 10,000 µM was used. N/A, not applicable; No current, no GABAmax-evoked peak-current amplitude exceeded 5 nA in
any of the tested oocytes.
aData were from n = 5 experiments performed on oocytes that had been incubated for 5–6 d following cRNA injection and selected based on GABAmax-evoked
current amplitudes; note that data for these n = 5 oocytes are not included in the number of oocytes tested or GABAmax results.
bGiven the GABA EC50 value at this construct combination, the utilized 316-µM GABAmax concentration represents a submaximal EC70–80 concentration; an
EC100 concentration would thus be expected to give values that are 20–30% larger.
cOnly 80–90% of the fitted curve is covered by data points (Fig. 9 C) and derived fitted values could therefore be seen as lower limits.
dThese values are derived from first-order fitting; however, data are statistically better represented by second-order fitting as described in the text.
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free subunits in a biased ratio, suggesting that receptors based
on linked tetramers resemble wild-type receptors.
Given the construct designs, only two simple (α1)2(β2)2(γ2)
receptor stoichiometries can arise in each case. These have all
linkers assembled in either the clockwise or the counterclock-
wise orientation (Fig. 4 E). However, in each case, only one of
these possibilities results in the canonical receptor with two
GABA-binding β2-α1 interfaces and a zolpidem-binding α1-γ2 in-
terface (Fig. 4 E, two lower receptors). The other possibility gives
a receptor with only one GABA-binding β2-α1 interface and no
zolpidem-binding α1-γ2 interface (Fig. 4 E, two upper receptors).
Therefore, functional receptors must be the result of assemblies
with the linkers of the α-10-β-α-β concatemer in the clockwise
orientation and the α-10-β-α-γ concatemer in the counterclock-
wise orientation.
Definition of “total linker length” and shortest possible
length predictions
As the N- and C-terminal ends differ considerably in their se-
quence and length among Cys-loop receptor subunits, there is a
need for a consensus to calculate linker lengths. For this pur-
pose, we used the method described by Ahring et al. (2018) in
calculating linker lengths for concatenated nAChR constructs.
The methodology establishes anchors based on conserved resi-
dues within the Cys-loop receptor family from which total
linker sequences are calculated. The end of the transmembrane
Table 2. Regression results from fitted zolpidem responses at wild-type and concatenated GABAARs
Zolpidem
Construct Subunit EC50 (µM) pEC50 n GABA316 µM (nA)
α1 + β2 1:50 No effect 7 2,100 ± 300
α1 + β2 50:1 No effect 6 750 ± 250
α1 + β2 + γ2 5:1:5 0.11 6.95 ± 0.02 11 2,900 ± 500
Dimeric constructs
β2-23-α1 γ2 0.10 7.00 ± 0.03 8 7,600 ± 700
α1-10-β2 γ2 0.18 6.74 ± 0.03 7 14,000 ± 6,000
α1-9a-β2 γ2 0.19 6.72 ± 0.03 14 7,000 ± 1,000
α1-6a-β2 γ2 0.15 6.83 ± 0.03 8 4,000 ± 500
α1-3a-β2 γ2 0.20 6.71 ± 0.04 7 5,600 ± 1,300
α1-0a-β2 γ2 0.21 6.68 ± 0.03 12 280 ± 50
Tetrameric constructs
α1-10-β2-α1-β2 γ2 0.10 7.00 ± 0.03 9 5,000 ± 500
α1-10-β2-α1-γ2 β2 0.092 7.04 ± 0.02 7 5,800 ± 400
Pentameric constructs
α1-(-1a)-β2-α1-β2-γ2 0.17 6.76 ± 0.02 6 150 ± 50a
α1-(-1a)-β2-α1-γ2-β2 0.19 6.72 ± 0.02 12 2,300 ± 300a
γ2-15a-β2-α1-β2-α1 0.15 6.82 ± 0.02 9 6,100 ± 1,200
γ2-13a-β2-α1-β2-α1 0.22 6.65 ± 0.02 11 4,400 ± 600a
γ2-11a-β2-α1-β2-α1 0.27 6.57 ± 0.03 12 2,000 ± 30a
γ2-10a-β2-α1-β2-α1 0.14 6.86 ± 0.02 11 1,700 ± 200a
γ2-9a-β2-α1-β2-α1 0.17 6.78 ± 0.03 14 800 ± 150a
Mutant constructs
α1-9a-β2 γ2(A118R) 3.4 5.46 ± 0.04 11 8,600 ± 1,100
α1-0a-β2 γ2(A118R) 2.0 5.70 ± 0.03 7 990 ± 90
α1R94A + β2 + γ2 5:1:5 0.20 6.71 ± 0.02 7 990 ± 110a
γ2-11a-β2-α1-β2-α1R94A 0.36 6.44 ± 0.03 11 350 ± 50a
γ2-11a-β2-α1-β2-α1R94A α1 0.20 6.71 ± 0.03 9 510 ± 130a
Data points were fitted to the Hill equation with bottom set to 0 and Hill slope set to 1 by nonlinear regression. Fitted potencies of zolpidem are presented as
EC50 in µM and pEC50 ± SEM where p = −Log for the indicated number (n) of individual oocytes. The average peak-current amplitudes obtained with
GABA316 µM applications are presented as mean ± SEM in nA for the tested oocytes. No effect, no positive enhancement of GABAcontrol-evoked currents was
observed.
aDue to the GABA EC50 value on this receptor, GABA316 µM applications do not represent a maximal EC100 concentration.
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segment 4 (TM4) of the first subunit and a hydrophobic residue
in α-helix 1 of the second subunit are chosen as anchor points to
represent the start and the end of the total linker, respectively
(Fig. 5 A). Hence, the term total linker length covers existing
C- (of the first subunit) and N-terminal (of the second subunit)
sequences aswell as the synthetic linker that connects both subunits.
When viewed from the top, the α-helix 1 motifs in a Cys-loop
receptor point in a clockwise orientation and are locked in a fixed
position by two hydrophobic patches (ILxxLL23 in α1 and
TVxxLL19 in β2) entrenched in hydrophobic pockets (Fig. 5 B).
Using the Ahring et al. (2018) methodology, the Ile18 residue in
the α1 subunit and the corresponding Thr14 residue in the
β2 subunit represent N-terminal anchors (Fig. 5 B and Table 3).
Note that, in this context, GABAAR β subunits represent outliers
in comparison with most mammalian Cys-loop receptor sub-
units. Instead of a hydrophobic leucine or isoleucine residue, β
subunits have a threonine residue that is traditionally considered
hydrophilic. However, with the methyl group pointing toward
the hydrophobic patch, it can still engage in hydrophobic con-
tacts to help anchor the α-helix 1 motif (Fig. 5 B).
The directional nature of the α-helix 1 motifs causes the
minimal required total linker length to differ between clockwise
and counterclockwise assemblies, with the latter being the
shortest. Predicted minimum lengths required to link the
α1 TM4 Leu416 anchor to the β2 Thr14 anchor were obtained
based on modeling of the α1-β2 and β2-α1 subunit interfaces
(Fig. 5 C). In the “short” counterclockwise orientation, a span of
minimally 27 amino acids was required, whereas the “long”
clockwise direction required minimally 30 amino acids (Fig. 5
C). Addition of fewer amino acids resulted in visual distortion of
the α1 TM4 segment and/or the β2 helix 1 following a short
geometry optimization indicative of a too short and constrained
linker. Thus, the shortest possible counterclockwise linker is
predicted to require three amino acids less than the shortest
Table 3. Total-linker-length calculations for concatenated GABAAR constructs
Subunit linking Total-linker-length calculation
Linked set C-term. Linker sequence N-term. End TM4 C-tail Linker N-term. to Anchor Anchor Sum
Dimeric constructs
β2-23-α1 LYYVN Q3(Q2A3PA)2AQ5 QPSLQ WLYYV 1 23 17 ILDRL 41
α1-10-β2 PTPHQ LQ9 QSVND WATYL 13 10 14 TVDRL 37
α1-9a-β2 PTPHQ (AGS)3 QSVND WATYL 13 9 14 TVDRL 36
α1-6a-β2 PTPHQ (AGS)2 QSVND WATYL 13 6 14 TVDRL 33
α1-3a-β2 PTPHQ AGS QSVND WATYL 13 3 14 TVDRL 30
α1-0a-β2 PTPHQ AGS NDPSN WATYL 13 3 11 TVDRL 27
α1-(-1a)-β2 PTPHQ AGS DPSNM WATYL 13 3 10 TVDRL 26
α1-(-2a)-β2 PTPHQ AGS PSNMS WATYL 13 3 9 TVDRL 25
α1-(-3a)-β2 PTPHQ AGS SNMSL WATYL 13 3 8 TVDRL 24
Tetrameric and pentameric constructs
α1first-10-β2second PTPHQ LQ9 QSVND WATYL 13 10 14 TVDRL 37
α1first-(-1a)-β2second PTPHQ AGS DPSNM WATYL 13 3 10 TVDRL 26
γ2first-15a-β2second SYLYL (AGS)5 QSVND SYLYL 1 15 14 TVDRL 30
γ2first-13a-β2second SYLYL S(AGS)4 QSVND SYLYL 1 13 14 TVDRL 28
γ2first-11a-β2second SYLYL GS(AGS)3 QSVND SYLYL 1 11 14 TVDRL 26
γ2first-10a-β2second SYLYL S(AGS)3 QSVND SYLYL 1 10 14 TVDRL 25
γ2first-9a-β2second SYLYL (AGS)3 QSVND SYLYL 1 9 14 TVDRL 24
β2second-α1third LYYVN (AGS)5LGS(AGS)3 QPSLQ WLYYV 1 27 17 ILDRL 45
α1third-β2fourth PTPHQ AGT(AGS)5 QSVND WATYL 13 18 14 TVDRL 45
α1third-γ2fourth PTPHQ AGT QKSDD WATYL 13 3 29 ILNNL 45
β2fourth-α1fifth LYYVN (AGS)4ATG(AGS)4 QPSLQ WLYYV 1 27 17 ILDRL 45
γ2fourth-β2fifth SYLYL (AGS)2ATG(AGS)5 QSVND SYLYL 1 24 14 TVDRL 39
The five most proximal C-terminal amino acids (C-term.), the specific linker sequences introduced during concatenation (Linker sequence), and the five first
amino acids from the predicted mature N terminus (N-term.) are presented for the indicated subunit pairs. Total-linker-lengths (Sum) are calculated as the sum
of all existing amino acids and introduced linker sequence between two artificial fix points “End TM4” and “Anchor.” The five most proximal amino acids in
TM4 (End TM4) and C-terminal tail lengths (C-tail) are obtained from UniProt (P14867 for α1 and P47870 for β2). The N-terminal lengths (N-term. to Anchor)
are derived from a definition of an α-helix 1 anchor (Anchor) as described in the text. For tetrameric and pentameric constructs, numbers in superscript indicate
the construct position of each subunit (e.g., β2second: β2 subunit in the second construct position).
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possible clockwise linker, which corresponds to ∼10 Å in dis-
tance difference.
Design of new dimeric constructs
The aim for designing new linked dimeric constructs is to
identify a potential linker length for which functional receptors
only originate from counterclockwise assembly of dimers. As
detailed in Ahring et al. (2018), short counterclockwise linkers
can be expected to pack tightly along the extracellular domain
of, in particular, the first subunit of a linked dimer (Fig. 5 C). In
cases where a linker packs tightly over the C-loop of a GABA-
binding interface this could be envisioned to affect normal
function. As β2-α1 dimers are more likely to be affected by this,
we chose to work with α1-β2 constructs. Furthermore, we de-
cided to use AGS-repeat linkers instead of poly-Q linkers. This
strategy was successful for nicotinic α4β2 receptors and is easily
Figure 2. Potency of GABA and zolpidem at GABAARs from concatenated β-23-α or α-10-β constructs. X. laevis oocytes were subjected to two-electrode
voltage-clamp electrophysiology and electrophysiological data were evaluated as described in the Materials and methods; also see Fig. 1. cRNA for β-23-α or
α-10-βwas injected alone (A, B, and C), coinjected with a free β2 subunit in a 1:1 ratio (A, B, and C), or coinjected with a free γ2 subunit in a 1:1 ratio (D, E, and F).
(A and D) GABAmax-evoked peak-current amplitudes are depicted as means ± SEM for receptors from the indicated cRNA mixtures. A GABA concentration of
316 µM was used as GABAmax. Data were obtained from n = 8–13 experiments and calculated averages are presented in Table 1. (B and E) GABA CRRs are
depicted as means ± SD for receptors from the indicated cRNA mixtures. Data were obtained from n = 8–13 experiments and regression results are presented
in Table 1. (C and F) Representative traces illustrating GABA CRRs at receptors from the indicated cRNA mixtures. Bars above the traces designate the 30-s
application time and concentrations of applied GABA. (G) Zolpidem enhancement CRRs are depicted as means ± SD for receptors from β-23-α + γ2 or α-10-β + γ2 co-
injections. Datasets from each oocyte were normalized to the maximal fitted response to enhance visual comparison of EC50 values. Data were from n =
7–8 experiments and regression results are presented in Table 2. (H) Representative traces illustrating zolpidem CRRs from G. Bars above the traces
designate the 30-s application time and concentrations of applied GABA and zolpidem.
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amenable for systematic shortening of the linker length and less
likely to deplete specific tRNAs than a poly-Q linker.
The β-23-α construct has a total linker length of 41 amino acids,
whereas the α-10-β construct has 37 amino acids (Fig. 5 A and
Table 3). Initially, five new dimeric α1-xa-β2 constructs with total
linker lengths of 36, 33, 30, 27, and 24 amino acids were created.
These were termed α-9a-β, α-6a-β, α-3a-β, α-0a-β, and α-(-3a)-β,
respectively. The nomenclature indicates how many amino acids
(a) are added or removed to link the two sequences. For restriction
site purposes, a minimum of one AGS repeat was introduced in all
cases. Thus, in order to create the two shortest constructs, it was
necessary to omit three and six existing amino acids, respectively,
during the linking process. As the predicted mature GABAAR
subunits generally have long N-terminal sequences upstream
from the α-helix 1 anchor, when compared with, for example,
nAChR subunits, we chose to omit these amino acids from the
β2 N terminus (QSV and QSVNDP, respectively; Table 3).
Shortened linker can lead to primarily counterclockwise
assembly of dimeric concatemers
With a construct that is restricted to the shorter counterclock-
wise assembly, coexpression with β2 should lead to fully func-
tional α1β2 receptors, whereas coexpression with γ2 should lead
to receptors with only one GABA-binding β2-α1 interface (Fig. 3
B, receptor 5).
α-xa-b alone
Average GABAmax-evoked peak-current amplitudes decreased
noticeably as the linker length was shortened (Fig. 6 A and
Table 1). No single oocyte exhibited current amplitudes ex-
ceeding 5 nA with the shortest (-3a)-linked construct. While
GABA-evoked currents were observed with the 0a-linked con-
struct, the amplitudes were deemed insufficient for performing
reliable GABA CRRs. For the remaining three constructs, GABA
gave rise to CRRswith EC50 values in the 3.2–10-µM range (Fig. 6
B and Table 1). The lowest potency was observed with the
shortest 3a-linked construct. No apparent differences were ob-
served when comparing current traces from injections of α-9a-β
and α-3a-β cRNA (Fig. 6 C).
α-xa-b + b2
Inclusion of free β2 subunits in the cRNA mixture led to robust
GABAmax-evoked peak-current amplitudes in most cases
(Fig. 6 D and Table 1). Although maximal current amplitudes
were only in the 40-nA range with the (-3a)-linked construct,
this was sufficient to perform full CRR experiments. All fitted
Figure 3. Possible GABAAR assemblies with concatenated β-23-α or α-10-β constructs. β2, α1, and γ2 subunits are illustrated as green, blue, and red
circles, respectively, viewed from the extracellular space. The pore-lining transmembrane helix 2 domain is indicated by circles embedding the symbol “II”.
Principal and complementary subunit faces are indicated with “+” and “-,” respectively. Linkers are shown as purple arrows progressing from the C terminus of
the first subunit to the N terminus of the second. Linker orientation(s) within a receptor complex deemed functional is indicated underneath each receptor by
orange (counterclockwise) or yellow (clockwise) arrows. Given no confirmed knowledge regarding the assembly orientation of linked β-23-α or α-10-β dimers,
numerous possible assemblies can be envisaged depending on the specific cRNA content. Note that only the simplest possibilities are illustrated; more complex
assemblies including di-pentamers or additional dangling subunits cannot be excluded. (A) Injection of the β-23-α or the α-10-β construct alone could lead to a
receptor pool containing from one to six different receptor assemblies. These receptors can be of both 2α:3β or 3α:2β stoichiometries and have a dangling α1 or
β2 subunit. Only the β-23-α case is illustrated; however, α-10-βwould give a fully similar scenario. (B) Coinjection of β-23-α + γ2 or α-10-β + γ2 could lead to a
receptor pool containing from one to three different receptors in each case. However, for each construct, only one of these assembly possibilities results in a
receptor with two canonical GABA-binding β2-α1 interfaces and a zolpidem-binding α1-γ2 interface (receptors 1 and 4). It is questionable whether the other
assembly possibilities are functional, although one assembly has a single canonical GABA-binding β2-α1 interface and a proposed GABA-binding β2-γ2 interface
(receptors 2 and 5).
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EC50 values for GABA CRRs were in the 1.7–4-µM range (Fig. 6 E
and Table 1). This is essentially identical to the 2.6 µM obtained
with receptors expressed with free subunits in a biased ratio
(Fig. 1 A). Despite the current amplitude differences, no other
visual difference was noted between current traces from α-9a-β +
β2 and α-(-3a)-β + β2 injections (Fig. 6 F).
α-xa-b + γ2
With construct linkers of 9a to 3a, GABAmax-evoked peak-
current amplitudes were substantial in the 3–11-µA range
when free γ2 subunits were included in the cRNA mixture
(Fig. 6 G and Table 1). The GABA CRRs revealed normal EC50
values in the 17–41-µM range for these receptors (Fig. 6 H and
Table 1). However, with the shorter 0a-linked construct, current
amplitudes dropped substantially to 0.5 µA, and interestingly
this was accompanied by a lower GABA potency of 130 µM.
Despite this change, no obvious visual differences were noted
between traces for α-9a-β + γ2 and α-0a-β + γ2 cRNA (Fig. 6 I).
The average current amplitude was marginal at ∼2 nA for n = 24
oocytes with the shortest (-3a)-linked construct, which is, in
general, too low for performing full CRR experiments (Table 1).
Clear GABA-evoked currents ranging from 2–4 nA were, how-
ever, observed in eight oocytes and a further two oocytes dis-
played amplitudes in the 5–22-nA range.
With respect to the aim of discovering a linker length that
only allows dimers to assemble in the counterclockwise orien-
tation, this appeared to be achieved with the α-(-3a)-β construct.
Yet, this exclusivity came at a cost of a substantial loss in peak-
current amplitudes when the construct was coexpressed with
free β2 subunits. Besides rendering the α-(-3a)-β construct
useless for most practical purposes, the current amplitude loss
also raises questions regarding receptor stoichiometry. Although
restricted from clockwise assembly, a construct with the optimal
total-linker-length should still express efficiently in the coun-
terclockwise orientation. Hence, the amplitude loss could sug-
gest that the observed currents are not solely from receptors
assembled in a simple scenario with two dimers and a free
β2 subunit; receptors might instead be a mixture of complex
scenarios where 2–3 free β2 subunits assemble with dimers,
such that linked β2 subunits end up dangling. Complex dimer
assembly scenarios of this kind were observed by Groot-
Kormelink et al. (2004) for nAChRs. The next-shortest α-0a-β
Figure 4. Potency of GABA and zolpidem at GABAARs from concatenated tetrameric constructs based on the α-10-β construct. X. laevis oocytes were
injected with cRNAmixtures for α-10-β-α-β + γ2 or α-10-β-α-γ + β2 and subjected to two-electrode voltage-clamp electrophysiology. Electrophysiological data
were evaluated as described in the Materials and methods; also see Fig. 1 and Fig. 2. (A) GABAmax-evoked peak-current amplitudes are depicted as means ±
SEM for receptors from the indicated cRNA mixtures. A GABA concentration of 316 µM was used as GABAmax. Data were obtained from n = 9–11 experiments
and calculated averages are presented in Table 1. (B) GABA CRRs are depicted as means ± SD for receptors from the indicated cRNA mixtures. Data were
obtained from n = 9–11 experiments and regression results are presented in Table 1. (C) Representative traces illustrating GABA CRRs at receptors from the
indicated cRNA mixtures. Bars above the traces designate the 30-s application time, and concentrations of applied GABA are indicated for each trace.
(D) Zolpidem enhancement CRRs are depicted as means ± SD for the indicated receptors. Data were from n = 7–9 experiments and regression results are
presented in Table 2. (E) Simplest potential receptor assemblies arising from injection of the tetrameric constructs with a free subunit. As the linked subunits
might assemble in either the clockwise or the counterclockwise orientation, each case leads to two different assemblies. Of these, however, only one give
receptors with two canonical GABA-binding β2-α1 interfaces and a zolpidem-binding α1-γ2 interface (lower panels).
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construct resulted in overall similar current amplitudes when
coexpressed with free β2 or γ2 subunits. To investigate whether
intermediate linker lengths would be superior, two additional
constructs termed α-(-1a)-β and α-(-2a)-β were created, which
have total linker lengths of 26 and 25 amino acids, respectively.
α-(-1a)-b and α-(-2a)-b
No GABAmax-evoked peak-current amplitudes exceeding
5 nA were observed with the (-1a)- and (-2a)-linked constructs
injected by themselves (Fig. 6 J). In contrast, coexpression
with free β2 subunits resulted in robust current ampli-
tudes in the 400-nA range. The fitted EC50 value for the
GABA CRR was 2.6 µM for both constructs (Fig. 6, K and L).
When coexpressed with free γ2 subunits, average current
amplitudes of ∼8 nA were observed (Table 1). While this is
overall too low for obtaining GABA CRRs, current ampli-
tudes in the 20–50-nA range were observed in 5–10% of the
oocytes.
Figure 5. Total linker calculations and 3-D structures of GABAAR interfaces. Total-linker-length calculations are based on a methodology developed
in Ahring et al. (2018). Besides added artificial linker sequences, C-terminal amino acids following the last residue in TM4 as well as N-terminal amino
acids preceding a hydrophobic anchor (I/T anchor) in α-helix 1 are also considered parts of the linker. (A) The β-23-α and the α-10-β constructs originally
designed by Baumann et al. (2001) have total linker lengths of 41 and 37 amino acids, respectively. Below these constructs, calculations for new con-
catenated α-xa-β dimer constructs are illustrated. Note that only partial cDNA sequences in the vicinity of the linkers is shown. (B) Top view of α1-β2-
α1 trimer interfaces highlighting the N-terminal α-helix 1 motifs. When viewed from the top, the helix motifs are pointing in a clockwise orientation. The
α1 subunit is colored green, β2 is blue, the α-helix 1 is red, anchor Ile/Thr residues are shown as red spheres, and hydrophobic areas within 4 Å of the anchors
are colored yellow. (C) α1-β2 dimer with modeled long clockwise and short counterclockwise linkers. The backbone of the linker is shown in white
space–filling representation. The least number of amino acids required to connect the last α1 residue in TM4 (Leu443) to the mature N terminus of β2 (Glu25)
was 13 and 16 residues, respectively. This corresponds to a total linker length of 27 and 30 residues (white) as calculated between anchors α1 Leu443 and
β2 Thr39 (Table 3).
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Figure 6. GABA potency at GABAARs from concatenated α-xa-β dimer constructs. X. laevis oocytes were subjected to two-electrode voltage-clamp electro-
physiology and electrophysiological datawere evaluated as described in theMaterials andmethods; also see Fig. 1. cRNA for α-xa-β constructs were injected alone (A, B,
C, and J), coinjectedwith amonomeric β2 subunit in a 1:1 ratio (D, E, F, J, K, and L), or coinjectedwith amonomeric γ2 subunit in a 1:1 ratio (G, H, I, and J). (A, D, G, and J)
GABAmax-evoked peak-current amplitudes are depicted as means ± SEM for receptors from the indicated cRNAmixtures. A GABA concentration of 316 µMwas used as
GABAmax for all construct combinations with the exception of α-10-β+γ2, for which a concentration of 3,160 µM was used. Data were obtained from n = 7–24 ex-
periments and calculated averages are presented in Table 1. (B, E, H, and K) GABA CRRs are depicted as means ± SD for receptors from the indicated cRNA mixtures.
Datawere obtained from n = 7–24 experiments and regression results are presented in Table 1. (C, F, I, and L)Representative traces illustrating GABACRRs at receptors
from the indicated cRNA mixtures. Bars above the traces designate the 30-s application time and concentrations of applied GABA are indicated for each trace.
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GABA CRRs for (-1a)-, (-2a)-, and (-3a)-linked constructs
coexpressed with γ2
When coexpressed with free γ2 subunits, the three shortest
constructs all resulted in low average current amplitudes, yet
some oocytes still expressed robustly. Since the GABA EC50
value for the 0a-linked construct is 130 µM, it could be specu-
lated that the EC50 values for the three shorter constructs are
further shifted toward lower potency, which might exclude
functional receptors from being detected by a GABAmax con-
centration of 316 µM. In an attempt to obtain GABA CRRs for
these construct combinations, a separate set of experiments was
performed using oocytes incubated for 5–6 d following injection
and selection of those that displayed GABAmax-evoked peak-
current amplitudes exceeding 20 nA. For each combination, a
total of n = 5 oocytes were identified and these had average
current amplitudes evoked by 10 mM GABA in the 53–100-nA
range, with the lowest value observed for the (-3a)-linked con-
struct. GABA EC50 values for the three combinations were in the
range of 64–140 µM, with the most potent value observed for the
(-3a)-linked construct (Table 1). Given the overall low current
amplitudes, these values appear similar andmatch that observed
with the (0a)-linked construct. While these data show that the
three constructs coexpressed with γ2 can give functional re-
ceptors, it is important to note that these separate experiments
required substantial oocyte selection, in particular for the (-3a)-
linked construct.
Overall, the picture with the new dimers is one where usage
of shorter linkers increases control of concatemer assembly.
Whereas the linker in the (0a)-linked construct is long enough
to allow some assembly with the γ2 subunit in the clockwise
orientation, the one in the (-3a)-linked construct is too short
even for efficient counterclockwise assembly with the β2 subu-
nit. In between, the (-1a)- and (-2a)-linked constructs express
efficiently and consistently in the counterclockwise orientation
with free β2 subunits but not in the clockwise orientation with
free γ2 subunits. Hence, a total-linker-length of 25–26 amino
acids appears suited for ensuring that functional receptors based
on dimeric α1-xa-β2 constructs originate from linkers assembled
primarily in the counterclockwise orientation.
Why does the GABA EC50 value differ between the dimeric
constructs coexpressed with γ2?
Whereas coexpression experiments of α1-xa-β2 dimeric con-
structs with free β2 subunits gave essentially identical GABA
EC50 values, irrespective of linker length, corresponding ex-
periments with free γ2 subunits revealed a noticeable shift be-
tween constructs with short versus long linkers. An EC50 value
of 130 µM was observed for the 0a-linked constructs, whereas
values in the 17–41-µM range were observed for longer linked
constructs (Fig. 6 H and Table 1). Given the ability of dimers with
long linkers to assemble into α1β2 receptors by themselves, it
appears likely that the EC50 value for, for example, the α1-9a-
β2 construct is influenced by pollutant α1β2 receptors. Still, the
approximately fourfold EC50-value difference between the α1-
3a-β2 and the α1-0a-β2 constructs coexpressed with γ2 appears
intriguing. Obviously, this could simply be a secondary effect of
short linkers since linked dimers must orient themselves in the
unfavorable long clockwise orientation to yield receptors in the
canonical βαβαγ assembly (Fig. 3 B, receptor 4). However, an-
other intriguing explanation could be that α1-0a-β2 + γ2 leads to
receptors with an alternative subunit arrangement. It was pre-
viously proposed that βγ receptors express functionally and
respond to GABA in the micromolar range (Whittemore et al.,
1996; Chua et al., 2015; Wongsamitkul et al., 2017). Hence, if the
linked α1-0a-β2 dimers orient themselves in the shortest coun-
terclockwise orientation, the γ2 subunit would be positioned
alternatively in a βαβγα assembly (Fig. 3 B, receptor 5). As-
suming that two agonist GABA-binding sites are necessary for
receptor activation, the EC50 value shift could then be the result
of lower GABA potency at the β2-γ2 interface.
To differentiate between these two possibilities, GABA and
zolpidem CRRs were compared at receptors from 9a- and 0a-
linked constructs coexpressed with either a wild-type γ2 or a
mutant γ2A79R subunit. The γ2A79 loop D residue is centrally
placed on the complementary side in the benzodiazepine
α1-γ2 binding pocket and corresponds to an important
GABA-binding arginine, α1R67, in the β2-α1 interface (Bergmann
et al., 2013). Thus, if receptors are of the canonical βαβαγ stoi-
chiometry (i.e., with dimers assembled in the long clockwise
orientation) the mutation should negatively affect the potency of
zolpidem in the α1-γ2A79R interface. However, if receptors are of
the alternative βαβγα stoichiometry (i.e., with dimers assembled
in the short counterclockwise orientation) the mutation should
increase the potency of GABA in the β2-γ2A79R interface. Inter-
estingly, the results from these experiments were clear cut.
Whereby the potency of GABA was affected by linker length, it
was not affected by the A79R mutation in γ2 (Fig. 7 A and
Table 1). In contrast, the potency of zolpidemwas not affected by
linker length but decreased by ∼10-fold with the γ2A79R subunit
mutation (Fig. 7 B and Table 2). This demonstrates that receptors
have the canonical βαβαγ stoichiometry in both cases.
The data exclude β2-γ2 interfaces as the cause for the argu-
ably small EC50 value shift between the 3a- and 0a-linked con-
structs.Moreover, themarginal current amplitudes observed for
the (-1a)- and (-2a)-linked constructs coexpressed with free
γ2 subunits in the previous section corroborate the notion that
β2-γ2 interfaces are not significantly contributing to receptor
activation for these constructs either. Hence, the most likely
explanation for the shift is secondary effects from inclusion of
short linkers; however, what this exactly constitutes remains
elusive. One possibility is that short linkers in the unfavorable
clockwise orientation cause tighter packing of the total receptor
complex. Another possibility is that the passage of short clock-
wise linkers across GABA-binding interfaces alters the mobility
of the β2 C-loop. While less likely, it also remains possible that
functional receptors from the 0a-linked construct contain more
than two dimers with associated interfering dangling subunits.
Using one short linker to force counterclockwise orientation
of pentameric concatemers
To evaluate whether a short first linker can force pentameric
concatemers to assemble with their linkers predominantly in
the counterclockwise orientation, two new constructs, α-(-1a)-β-
α-β-γ and α-(-1a)-β-α-γ-β, weremade by extending the α-(-1a)-β
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construct (Table 3). Note, that these constructs vary primarily
by the positions of the last two subunits. The linker sequences
introduced to fuse the β2second-α1third, α1third-β2fourth, or
α1third-γ2fourth subunit pairs were identical to those used for
the tetrameric constructs above. An (AGS)4ATG(AGS)4 linker
was used for the β2fourth-α1fifth pair and consisted of 27 amino
acids, which essentially can be subdivided into nine AGS re-
peats with one repeat altered from AGS to ATG to allow in-
troduction of a unique restriction (AgeI) site (Table 3). Fusion
of the γ2fourth-β2fifth subunit pair was obtained with a similar
but one repeat shorter (AGS)2ATG(AGS)5 linker. Although
that results in a total linker length of 39 instead of the stan-
dard 45 amino acids, this still appears substantially longer
than minimally needed.
Whereas injection of both constructs gave rise to GABA-
evoked currents, the maximal current amplitude levels
differed substantially (Fig. 8 A and Table 1). With average
amplitudes of 320 nA for α-(-1a)-β-α-β-γ and 3,500 nA for
α-(-1a)-β-α-γ-β the difference was ∼11-fold; however, this
underestimates the actual difference between randomly cho-
sen oocytes, as ∼25% of the oocytes for α-(-1a)-β-α-β-γ were
discarded due to low GABAmax-evoked peak-current ampli-
tudes. The GABA and zolpidem CRRs revealed similar fitted
EC50 values in the 330–390-µM and 0.17–0.19-µM ranges,
respectively (Fig. 8, B–D; Table 1; and Table 2). This demon-
strates that efficient expression of functional receptors only
occurs with the concatemers in a counterclockwise assembly
once the first construct linker is short (Fig. 8 E). That said,
the ∼10-fold lower GABA potency at both pentamers in com-
parison with, for example, data for tetramers was a surprising
observation (Table 1).
Optimizing the design of pentameric constructs
Why the α-(-1a)-β-α-γ-β construct resulted in a notably shifted
GABA EC50 value of 330 µMwhen the concatemer has the ability
to assemble efficiently in the optimal counterclockwise orien-
tation is unclear.We speculate that the reason for this might be a
complex combination of a short first linker and the specific
position of the γ2 subunit within the construct. Possibly, it is
generally unfavorable to have the γ2 subunit linked in both its N
and C termini. To investigate this, we created a set of new
pentameric constructs in which the γ2 subunit was only linked
at the C terminus. These were termed γ-xa-β-α-β-α and have a
first AGS-repeat–based linker addition of x = 15, 13, 11, 10, or 9
amino acids, which correspond to total linker lengths of 30,
28 26, 25, and 24 amino acids, respectively (Fig. 9 A and Table 3).
Note that these total linker lengths correspond to dimeric con-
structs ranging from α-3a-β (30 amino acids) to α-(-3a)-β (24
amino acids). The linker sequences used to fuse the β2second-
α1third, α1third-β2fourth, and β2fourth-α1fifth subunit pairs were
identical to those for the pentameric constructs above. When
assembled in the counterclockwise orientation, these new con-
catemers all yield the canonical βαβαγ receptor.
While injections of 15a-, 13a-, 11a-, and 10a-linked constructs
gave rise to maximal GABA-evoked current amplitudes in the
3.1–5.3-µA range, the shortest 9a-linked construct displayed
lower current amplitudes of 0.89 µA (Table 1). GABA CRRs re-
vealed EC50 values in the 51–120-µM range (Fig. 9 B and Table 1).
This is similar to the 70–80-µM values observed previously with
a pentameric construct or mixtures of dimeric and trimeric
constructs (Baur et al., 2006; Söderhielm et al., 2018). Zolpidem
displayed essentially identical CRRs with EC50 values in the
0.14–0.27-µM range, thereby mimicking that observed for free
subunits in a biased ratio (Table 2).
While the data do suggest that shortening of the first linker in
a γ-xa-β-α-β-α construct can have a secondary effect on GABA
potency, the EC50 values obtained with these constructs are all
within a narrow 2.4-fold range that span what was observed
with concatenated constructs previously. Furthermore, the
current amplitude data essentially mirror those observed with
the dimeric α-xa-β constructs to show that expression levels of
functional receptors decrease markedly once total linker lengths
are shortened below 25 amino acids. Hence, the γ-11a-β-α-β-α
construct represents a fair direct comparison to the α-(-1a)-
β-α-γ-β construct tested in the previous section and both have
total linker lengths of 26 amino acids in their first linker. Judged
by the difference in GABA potency, pentameric constructs with
the γ2 subunit in the first construct position appear better suited
for linker-length optimizations than those with γ2 in a center
position.
Figure 7. GABA and zolpidem potency at
wild-type or mutant concatenated GABAARs.
X. laevis oocytes were subjected to two-
electrode voltage-clamp electrophysiology and
electrophysiological data were evaluated as de-
scribed in the Materials and methods; also see
Fig. 1. cRNA for dimeric α-9a-β or α-0a-β con-
structs were mixed with cRNA for the wild-type
γ2 or mutant γ2A79R subunit in a 1:1 ratio.
(A) GABA CRRs are depicted means ± SD for
receptors from the indicated cRNA mixtures.
Data were obtained from n = 9–20 experiments
and regression results are presented in Table 1.
(B) Zolpidem enhancement CRRs are depicted as
means ± SD for the indicated receptors. Data
were from n = 7–14 experiments and regression
results are presented in Table 2.
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Does a pentameric construct ensure a uniform receptor pool?
An important point to consider when working with concate-
nated pentameric constructs is whether resultant receptors are
actually as expected. It might, for example, be speculated that
linker proteolysis could lead to the existence of shorter con-
taminating concatemers or even free subunits inside oocytes.
Fortunately, several studies of pentameric nAChR concatemers
have shown that linker proteolysis is not a problem for con-
structs where the signal peptides are omitted for all but the first
subunit (Carbone et al., 2009; Kuryatov and Lindstrom, 2011).
Nevertheless, other avenues could still lead to expression of
undesired receptors. The open-reading frame for a pentameric
GABAAR construct is in the vicinity of 7,000 bp. Despite opti-
mization of the experimental conditions for long transcripts, it
remains possible that premature termination during cRNA
synthesis could lead to pollutant incomplete cRNA entities.
Partial degradation of cRNA inside oocytes could potentially
give the same result. Concatemers from such incomplete cRNA
entities might then assemble with each other or even with
full-length concatemers to give unexpected receptors with
dangling subunits.
To investigate whether receptors originate from full-length
concatemers we created a new γ-11a-β-α-β-αR67A construct. The
α1R67 loop D residue represents an important GABA-binding
arginine residue in a wild-type β2-α1 interface (Bergmann
et al., 2013). Previous coexpression of rat α1R66C (R66 in rat
α1 corresponds to R67 in human α1) or human α1R67A with
β2 subunits led to a substantial loss in GABA potency from a
6–80-µM range to a 1–30-mM range (Boileau et al., 1999;
Goldschen-Ohm et al., 2011). The new γ-11a-β-α-β-αR67A con-
struct contains both a wild-type and a mutant α1 subunit, and
hence full-length concatemers have both a wild-type β2-α1 and a
mutant β2-α1R67A GABA-binding site. The two sites have dif-
ferent affinity for GABA; however, as GABA binding in both sites
is a requirement for efficient receptor activation, resultant
functional GABA potency should only represent binding to the
lower-affinity β2-α1R67A site. Thus, receptors derived from a
single concatemer are expected to have low 1–3-mM GABA
Figure 8. GABA and zolpidem potency at GABAARs from concatenated pentameric constructs with a short first linker. X. laevis oocytes were injected
with cRNA for the pentameric α-(-1a)-β-α-β-γ or α-(-1a)-β-α-γ-β constructs and subjected to two-electrode voltage-clamp electrophysiology. Electrophysi-
ological data were evaluated as described in the Materials and methods; also see Fig. 1 and Fig. 2. (A) GABAmax-evoked peak-current amplitudes are depicted as
means ± SEM for receptors from the indicated cRNA mixtures. A GABA concentration of 316 or 1,000 µM was used as GABAmax. Data were obtained from n =
10–12 experiments and calculated averages are presented in Table 1. (B) GABA CRRs are depicted as means ± SD for receptors from the indicated cRNA
mixtures. Data were obtained from n = 10–12 experiments and regression results are presented in Table 1. (C) Representative traces illustrating GABA CRRs at
receptors from the indicated cRNA. Bars above the traces designate the 30-s application time and concentrations of applied GABA are indicated for each trace.
(D) Zolpidem enhancement CRRs are depicted as means ± SD for the indicated receptors. Data were from n = 6–12 experiments and regression results are
presented in Table 2. (E) Potential receptor assemblies arising from injection of the two pentameric constructs. The respective pentamers can assemblewith all
linkers in either the clockwise or the counterclockwise orientation. Only one of these assemblies leads to receptors with two canonical GABA-binding
β2-α1 interfaces and a zolpidem-binding α1-γ2 interface (lower panels). A functional α-(-1a)-β-α-β-γ pentamer requires its linkers to assemble in the
longer clockwise orientation (Long way), whereas a functional α-(-1a)-β-α-γ-β pentamer assembles with its linkers in the shorter counterclockwise
orientation (Short way).
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potency, whereas receptors originating from mixtures of in-
complete concatemers missing the α1R67A subunit would be ex-
pected to have normal ∼100-µM GABA potency.
Corroborating previous data, coexpression of free α1R67A,
β2, and γ2 subunits in a 5:1:5 biased ratio gave rise to receptors
that had a GABA EC50 value of 1.1 mM (Fig. 9 C and Table 1).
However, with average maximal GABA-evoked current am-
plitudes of 7.1 µA and a zolpidem potency of 0.20 µM, the
mutated α1R67A subunit appeared to have no bearing on ex-
pression efficiency or zolpidem binding (Fig. 9 D, Table 1, and
Table 2). Injection of the γ-11a-β-α-β-αR67A construct led to
similar observations with an average maximal GABA-evoked
current amplitude of 3.6 µA, a GABA EC50 value of 2.6 mM,
and a zolpidem EC50 value of 0.36 µM (Fig. 9, C and D; Table 1;
and Table 2). As expected, the functional potency of GABA is
dictated by the lower-affinity β2-α1R67A site, and data for this
construct are fully consistent with a uniform receptor pool of
βαβαR67Aγ receptors.
In a final experiment, cRNA for γ-11a-β-α-β-αR67A and wild-
type α1 was mixed in a 5:1 ratio. Assuming equally efficient
protein translation, this ratio should give similar copy numbers
of concatemers and free α1 subunits inside oocytes. The GABA
and zolpidemCRRs for this mixture had an EC50 value of 2.0mM
and 0.20 µM, respectively, which appears similar to the values
observed for γ-11a-β-α-β-αR67A alone (Fig. 9, C and D; Table 1;
and Table 2). Yet, despite similar zolpidem potencies, the ob-
servedmodulatory efficacy at the 5:1 mixture was 190% ± 4%, n =
9, which is threefold lower than the 580% ± 10%, n = 11, for the
concatemer alone. Given the apparent similar GABA potency and
identical conditions in the zolpidem modulator experiments,
this suggests that the 5:1 pool contains a population of receptors
that does not respond efficiently to zolpidem under these
Figure 9. Design of new concatenated constructs and associated GABA potencies. X. laevis oocytes were injected with cRNA for the indicated pentameric
constructs termed 1–6, α1R67A + β2 + γ2 in a 5:1:5 ratio or construct 6 + α1 in a 5:1 ratio and subjected to two-electrode voltage-clamp electrophysiology.
Electrophysiological data were evaluated as described in the Materials and methods; also see Fig. 1 and Fig. 2. (A) Pentameric constructs with the γ2 subunit in
the first construct position were designed to contain a unique restriction site in each of the four linkers. Whereas the total linker lengths of the first linker for
constructs 1–5 were 30, 28, 26, 25, and 24 amino acids, respectively, the remaining three linkers had total lengths of 45 amino acids as presented in Table 3.
Construct 6 contained a point-mutated α1R67A subunit in the fifth construct position. (B and C) GABA CRRs are depicted as means ± SD for receptors from the
indicated cRNAmixtures. Data were obtained from n = 10–17 experiments and regression results are presented in Table 1. (D) Zolpidem enhancement CRRs are
depicted as means ± SD for the indicated receptors. Data were from n = 7–11 experiments and regression results are presented in Table 2. (E) GABA CRR data
for the 6 + α1 cRNA mixture from C were re-evaluated and a second-order equation represented the best fit as determined by an F test [F(1,77) = 10.1, P =
0.0022]. The fraction of the highest potency component was 0.12 and the derived potencies are indicated in the panel. Besides the biphasic graph fitted to the
actual data, two simulated graphs are added (dotted black lines) to represent each of the two components determined by the fitting routine.
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conditions. Further analysis revealed that while the GABA CRR
data for γ-11a-β-α-β-αR67A alone could only be fitted by a single-
order equation (second-order fit ambiguous), those for γ-11a-
β-α-β-αR67A + α1 were best approximated by second-order fitting
[F(1,77) = 10.1, P = 0.0022]. Approximately 12% of the recorded
current came from receptors with an EC50 value of 140 µM and
the remaining 88% from receptors with an EC50 value of 2.6 mM
(Fig. 9 E). The receptors with an estimated GABA potency of
140 µM obviously lack the α1R67A subunit and most likely orig-
inate from pentameric concatemers assembled with a free
α1 subunit, leaving a dangling α1R67A subunit or incomplete
concatemers assembled. Nevertheless, with the GABAcontrol
concentration of 100 µM used in the zolpidem experiments,
these receptors would be ∼50% activated and respond relatively
little to additions of zolpidem.
Overall, these data suggest that when the pentameric γ-11a-
β-α-β-αR67A construct is injected by itself, the resultant receptor
pool contains a uniform receptor population. This does not fully
exclude the possible existence of minute populations of con-
taminating receptors, such as di-pentamers with dangling sub-
units; however, if present, these appear to be negligible. In the
experiment with the mixture of γ-11a-β-α-β-αR67A + α1, ∼12% of
the total current originated from receptors with two wild-type
α1 subunits. That said, it is important to note that this is an
extreme scenario where the copy number of free α1 subunits
matches that of the concatemers. The fact that almost 90% of the
receptors originated from only concatemers suggests that in-
clusion of all five linked subunits is the preferred assembly for
pentameric constructs.
Discussion
The Sigel group published the design of the β-23-α and α-10-β
constructs in 2001 followed by additional construct designs to
include a γ2 subunit in 2002 (Baumann et al., 2001, 2002). Since
then, these constructs have set precedence for how to concate-
nate GABAARs. The determined linkers were considered optimal
and a scheme for how to calculate linker lengths for new con-
structs was devised (Minier and Sigel, 2004). Furthermore,
these studies were accompanied with receptor illustrations,
in which the linked subunits were drawn as assembling in
a counterclockwise orientation when viewed from the
extracellular space.
Initially, we tested resultant receptors from injections of the
original β-23-α and α-10-β constructs by themselves or in
combination with a monomeric β2 or γ2 subunit and our data
generally match the original findings of Baumann et al. (2001),
with one notable exception. When injected alone, both con-
structs gave rise to substantial GABA-evoked currents in our
experiments. This was not reported originally, although careful
examination of the data in Baumann et al. (2001) reveals low
levels of dimer-only expression. Later publications from the
Sigel group also note the existence of functional receptors from
expression of dimeric constructs by themselves (Kaur et al.,
2009; Sigel et al., 2009; Baur and Sigel, 2017). Nevertheless,
the key point is that dimers from both constructs assembled
readily into fully functional receptors, likely with dangling
subunits (Fig. 3 A). This is important when interpreting data
from experiments where dimeric constructs are mixed with free
subunits or other concatenated constructs. With the possibility
of dangling subunits in the equation, a resultant receptor pool
could contain additional unanticipated receptors.
While our data for β-23-α and α-10-β resemble the original
findings in Baumann et al. (2001), our view of how these data
should associate with schematic receptor drawings differs substan-
tially. To account for the observation that both the β-23-α + γ2 and
α-10-β + γ2 combinations give rise to receptors that are essentially
identical with respect to both GABA and zolpidem CRRs, the β-23-α
concatemer has to adopt the counterclockwise orientation (Fig. 3 B,
receptor 1), whereas the α-10-β has to adopt the clockwise orienta-
tion to form a receptor with two GABA-binding interfaces and one
zolpidem-binding interface (Fig. 3 B, receptor 4). Our conclusion is
therefore that these two dimers assemble in opposite orientations
when coexpressedwith a γ2 subunit to form canonical GABAARs. To
substantiate this, we created two new concatenated tetrameric
constructs based on α-10-β. As expected, functional receptors as-
sembled readily with the linked tetramers in opposite orientations
depending on the specific subunit order within the construct
(Fig. 4 E).
We recently demonstrated that long linkers in published
concatenated dimeric nAChR constructs result in subunit as-
sembly in both the clockwise and the counterclockwise ori-
entations (Ahring et al., 2018). The linkers of β-23-α and α-10-β
likewise appear sufficiently long to allow a similar situation for
GABAARs. Based on studies of 3D structures of Cys-loop re-
ceptors, the counterclockwise orientation should, however,
represent the shortest way for a linker. Therefore, in an attempt
to constrain assembly to a predominant counterclockwise ori-
entation, we created a range of new dimeric α-xa-β constructs.
These were expressed alone or coexpressed with free β2 or
γ2 subunits. Two key observations emerged from these ex-
periments. First, expression of functional dimer-only receptors
with dangling subunits appear less prominent as the linker is
shortened, which certainly is desirable as such receptors may
cloud interpretation of functional data. Second, identification of
a linker length that would restrict assembly of dimers to the
counterclockwise orientation required substantial optimization,
and only the α-(-1a)-β and α-(-2a)-β constructs resulted in the
desired outcome.
There are numerous published studies where schematic
drawings of concatenated receptors have been associated with
functional data for monomeric, dimeric, and trimeric construct
combinations. Given that many of these constructs can give rise
to receptors with dangling subunits and that the orientation
of concatemers can change depending on the circumstances,
the respective conclusions may be erroneous. For example,
Botzolakis et al. (2016) proposed several novel receptor GABAAR
stoichiometries and, among these, one where a γ subunit sub-
stitutes for a β subunit to give a βαγαγ receptor (viewed coun-
terclockwise from the extracellular space). This non-canonical
receptor assembly was suggested based on receptors formed
from expressing a dimeric α-γ construct with free β subunits.
However, in light of our data, the receptors formed could simply
include two dimers and two free β subunits in a canonical βαβαγ
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assembly with a dangling γ subunit. This seems a rather likely
explanation and similar scenarios have been demonstrated for
nAChRs (Groot-Kormelink et al., 2004). In another example,
Kaur et al. (2009) suggested that a GABAAR δ subunit can sub-
stitute for the α-subunit to give a GABA-binding β-δ interface.
This was evidenced by coexpressing a mixture of concatenated
α-β-α and β-δ constructs and associating the data with a sche-
matic drawing of an αβαβδ receptor. However, if the β-δ dimer
assembled in the opposite orientation, the resulting receptor
would have a βαβαδ stoichiometry with two canonical β-α
GABA-binding interfaces.
In light of all the potential issues observed with mixtures of
dimeric constructs and free subunits, we sought to make pen-
tameric constructs with restricted assembly orientation to
evaluate their utility for future studies. By extending the already
optimized α-(-1a)-β dimeric construct it proved possible to ob-
tain new constructs for which assembly clearly favored the
counterclockwise orientation. This was demonstrated by de-
signing two constructs, such that functional receptorsmust arise
from assembly in opposite orientations: clockwise for α-(-1a)-
β-α-β-γ and counterclockwise for α-(-1a)-β-α-γ-β. Although
receptors for the two constructs appeared functionally identical,
the one designed for counterclockwise assembly resulted, as
expected, in 11-fold greater current amplitudes. However, much
to our surprise, this came with an ∼10-fold shift in GABA po-
tency and therefore a set of five new constructs were created.
These had the γ2 subunit in the first construct position and
different first linker lengths (γ-xa-β-α-β-α). With respect to
GABA potency, these constructs all appeared within the normal
range and are therefore superior in comparison with the α-(-1a)-
β-α-γ-β construct. Depending on the specific need, one or more
of these constructs would therefore be well suited for future
studies.
In a final set of experiments, we investigated whether re-
sultant receptors from a pentameric construct with a short first
linker are actually the ones expected. Obviously, a pentameric
construct contains four linkers of which only the first linker
length was optimized in our constructs. Hence, it is plausible
that contaminating incomplete concatemers could assemble
with each other or with full-length concatemers to create
functional receptors with dangling subunits. With linkers 2–4
being longer than linker 1, dangling could occur in any of these
positions; however, for steric reasons, it appears improbable
that dangling would only involve one or two of the middle
subunits. If dangling occurs, it would be expected to always
include the subunit on the fifth position. Thus, we created a
construct with a reporter R67A mutation in the fifth construct
position α1 subunit (γ-11a-β-α-β-αR67A). The α1R67A mutation
lowers the GABA potency of resultant mutant receptors by ∼50-
fold, thereby making it obvious if a receptor pool contains wild-
type receptors along with mutant receptors. Data with this
mutant construct demonstrated that when the pentameric
construct was injected by itself, the receptor pool appeared
uniform for all practical purposes.
The large number of GABAAR subunits and their ability to
assemble in many stoichiometries represent a substantial chal-
lenge in the field. Recent publications suggesting that α, β, and γ
subunits are interchangeable have only added to the existing
knowledge chaos (Baur et al., 2009, 2010; Kaur et al., 2009;
Botzolakis et al., 2016; Wongsamitkul et al., 2017). However, we
speculate that many of these findings may not hold true once
revisited. In our studies with coexpression of α-xa-β dimers
with γ2, we observed a three- to fourfold lower GABA potency at
α-0a-β + γ2. In the simplest scenarios, this cRNA combination
can give rise to three possible receptor combinations: the con-
ventional βαβαγ receptor and two rearranged stoichiometries,
βαβγα and ββαγα, thereof (Fig. 3 B; receptor 4, 5, and 6, re-
spectively). Given that βγ receptors have been proposed to be
fully functional with GABA potencies in the micromolar range
(Whittemore et al., 1996; Chua et al., 2015; Wongsamitkul et al.,
2017), we were interested in evaluating whether a βαβγα re-
ceptor (Fig. 3 B, receptor 5), with its canonical GABA-binding
β-α interface and a potential GABA-binding β-γ interface, rep-
resents a functional constituent in the receptor pool. Intro-
duction of a key arginine (corresponding to α1R67) in the
complementary face of the γ2 subunit, however, revealed no
evidence that β-γ interfaces participate in GABA-mediated
activation in these experiments. Hence, despite optimal con-
ditions for formation of a functional βαβγα receptor, no evi-
dence of its existence was noted.
High-affinity GABA binding to the β-α interface is dependent
on specific determinants residing on both the principal β and the
complementary α face. The most important include the aromatic
box residues and the key arginine residue corresponding to α1R67
as shown previously (Bergmann et al., 2013). All α subunits have
an arginine in this position as also do the π and ρ subunits;
however, β, γ, and δ subunits do not. GABA can certainly bind in
interfaces that lack this arginine as exemplified by expression of
β3 homomers in oocytes (Chua et al., 2015) and by our experi-
ments with the γ-11a-β-α-β-αR67A construct, albeit with a sig-
nificant loss in potency. For the homomeric β3 receptor, GABA
activation occurs at concentrations in excess of 10 mM and we
observed potencies in the 1–3-mM range for γ-11a-β-α-β-αR67A.
We therefore suggest that it is unlikely that β-β, β-γ, or β-δ
interfaces contribute to GABA activation of a receptor within a
normal 1-µM to 1-mM concentration range. Hence, the chaos
surrounding GABAAR assemblymay actually be less chaotic than
recent data seem to suggest.
Conclusion and future directions
Our data emphasize that great care should be taken when in-
terpreting data based on the widely used concatenated con-
structs, especially where they are associated with oversimplified
schematic drawings of a GABAAR. Fortunately, our data dem-
onstrate that it is possible to optimize constructs such that
concatemer assembly is restricted to the counterclockwise ori-
entation, albeit this might require substantial efforts depending
on the need and the specific subunits involved. A striking lesson
was the complexity associated with the use of dimeric con-
structs, since a fine-tuning effort involves combatting not only
the assembly orientation possibilities but also the inherent
ability for assembly with dangling subunits. Hence, our data
suggest that pentameric constructs should be used for applica-
tions that require a high degree of control over the assembly
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process. Finally, while our work presents a way forward, there is
still room for further refinement. Pentameric constructs contain
four linkers and while we have addressed the first, it seems
logical to also pay attention to the other three linkers in future
constructs. Although less-flexible linkers in more positions
would likely increase the probability of obtaining only the de-
sired receptors, shortening of the last linker seems an obvious
avenue as that can potentially also limit dangling of the fifth
subunit.
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